Invention Grant
US08093268B2 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
失效
包含2-甲氧基-5-（5-三氟甲基 - 四唑-1-基 - 苄基） - （2S-苯基哌啶-3S-基） -
- Patent Title: Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
- Patent Title (中): 包含2-甲氧基-5-（5-三氟甲基 - 四唑-1-基 - 苄基） - （2S-苯基哌啶-3S-基） -
-
Application No.: US12524434Application Date: 2008-01-21
-
Publication No.: US08093268B2Publication Date: 2012-01-10
- Inventor: Giuseppe Alvaro , Charles Large
- Applicant: Giuseppe Alvaro , Charles Large
- Applicant Address: GB Greenford, Middlesex
- Assignee: Glaxo Group Limited
- Current Assignee: Glaxo Group Limited
- Current Assignee Address: GB Greenford, Middlesex
- Agent Kathryn L. Coulter
- Priority: GB0701364.2 20070124; GB0701365.9 20070124; GB0701366.7 20070124; GB0701367.5 20070124; GB0701368.3 20070124
- International Application: PCT/EP2008/050621 WO 20080121
- International Announcement: WO2008/090114 WO 20080731
- Main IPC: A61K31/454
- IPC: A61K31/454
Abstract:
The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifluoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl-piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.
Public/Granted literature
Information query
IPC分类:
